Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets.

Christoph Grothe Falk SteffenStefan Bittner

Published in: Journal of central nervous system disease (2021)

Treatment with cladribine tablets did not impair humoral response to COVID-19 vaccination. Time since last cladribine dose, age, prior therapy, lymphocyte count as well as B- and T-cell counts had no effect on seropositivity of anti-SARS-CoV-2 IgG antibodies.

Keyphrases

sars cov
immune response
peripheral blood
multiple sclerosis
coronavirus disease
respiratory syndrome coronavirus
dendritic cells
toll like receptor
white matter
combination therapy
stem cells